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Aim: To demonstrate the effects of local application of
Cidofovir in children with recurrent laryngeal papillomatosis
(RLP), according to our 2002 institutional protocol for RLP
management. Study Design: Preliminary/clinical
prospective. Material and Method: Our series included 5
RLP pediatric patients assisted at the otolaryngology pediatric
clinic at the Federal University of Sao Paulo. They were all
submitted to local application of Cidofovir and had up to a
one-year follow-up. Before starting the treatment with
Cidofovir, these patients had been submitted to at least three
surgical procedures with histopathological exams confirming
the diagnosis of papillomatosis (inclusion criteria); with no
clinical evidence of nephropathy or hepatic disorders
(exclusion criteria). The protocol consisted of surgical
removal of the lesions, followed by local application of 3 ml
of Cidofovir (7.5mg/ml). The treatment cycle included
minimum of 3 applications, and at any sign of recurrence,
another cycle of application would begin. Results: We
observed that before the use of Cidofovir, recurrences in all
5 children had shorter intervals (one each three months).
After Cidofovir application, the evolution of the illness
changed dramatically and the 5 patients did not need any
debulking for more than one year. No children presented
laboratorial exams alteration, local or systemic collateral
effects with local injection of Cidofovir. Based on our
preliminary results we observed that local application of
Cidofovir in children promotes good short-term control of
RLP recurrences.
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INTRODUCTION
Recurrent laryngeal papillomatosis (RLP) is a disease
whose main characteristic is the presence of verruciform
epithelial lesions that may be pedicle or sessile, single or
multiple, but which are, usually, recurrent lesions1. This clinical
entity leads to high morbidity because these lesions are
confluent and develop into dysphonia (voice disorders) and
dyspnea (changes in the respiratory pattern), both
progressive conditions. The lesions may trigger respiratory
failure due to airway obstruction and can even cause death.
Recurrences have frustrated ENT doctors for several decades.
In the specialty, this disease is considered as one of the
most difficult conditions to control. The lesions affect mainly
the larynx but may also affect the mouth, nose, pharynx,
esophagus and the whole tracheobronchial tree. In the larynx,
the most affect sites are the vocal folds, the epiglottis and
the vestibular folds. Other common sites are: the nasal ves-
tibular lumen, nasopharyngeal surface of the soft palate,
carina and the bronchi2.
This epithelial proliferation, considered a benign
neoplasia, is caused by human papillomavirus (HPV)
infection, a multiple type DNA virus. HPV-6 and HPV-11
types are the most common in laryngeal papillomatosis, but
we may also see HPV-16 and HPV-18 types,3-6 which may
have malignancy potential. Fortunately, we seldom find HPV-
16 and HPV-18 types in children with RLP6, but one must
always request HPV typing and, whenever these two types
are present, one must consider higher malignancy potential.
Although this is a benign disease, its clinical evolution
implies frequent hoarseness and upper airway obstruction
relapses. Thus, patients are often submitted to multiple
surgeries. Children usually have more aggressive relapses
and poorer prognosis. Doyle, in 19947, while studying
patients with severe recurrent laryngeal papillomatosis
showed, in his series, that although no adults had to be
submitted to tracheotomy, 60% of children were submitted
to tracheotomy.
Relapse control requires excessive larynx
manipulations, which may lead to permanent sequelae such
as stenosis, formation of anterior and posterior membranes,
vocal fold lesions, formation of granulation tissue, among
other disorders. 4,7,8.
Different therapeutic approaches have been
developed for treating recurrent laryngeal papillomatosis:
larynx microsurgery with mechanical removal or CO2 laser
removal; the use of anti-metabolites, hormones, podophyllin,
alpha interferon, indol-3-carbinol, photodynamic therapy and
antiviral agents. The antiviral agents that have already been
used in RLP are Acyclovir, Ribavirin and Cidofovir. As Acyclovir
and Ribavirin have shown poor results, the most used antiviral
agent has been Cidofovir.
Cidofovir [(S)-1-(3-Hydroxy-2-Phosphonyimethoxypropyl)
Cytosine, HPMPC, Vistide®] is an antiviral that has been proven
quite effective in the inhibition of virus replication such as herpes,
adenovirus, cytomegalovirus and papillomavirus 14-16. This drug
has been approved by the FDA (Food and Drug Administration)
to be used in retinitis caused by cytomegalovirus in patients with
AIDS. The first reports on the use of Cidofovir were published in
1993, by Kurtzman et al.14, showing the outcomes in animals.
Snoeck et al.17, 1995 were the first researchers to use Cidofovir in
humans with anal lesions caused by HPV. They used a gel
formulation in three patients with good outcomes. Its use in RLP
was first reported by Snoeck in 199816. Since then, several authors
have been showing positive outcomes with the use of this
medication in RLP treatments. 18-25. If administered by IV it may
cause hepatotoxicity and nephrotoxicity but, when used as local
applications, there has been no report of any type of local or
systemic side effects.
The use of Cidofovir as treatment for recurrent
laryngeal papillomatosis is quite recent. Nevertheless, the
studies that have been published are unanimous about its
absolute efficacy although there are some differences
regarding the standardization of its use in controlling the
relapses and its proper administration. For this reason, we
must carry out more standardized and controlled studies with
the drug so that we may assess cure expectations or relapses
control.
The objective of this study is to show, by means of
this preliminary report, the effects of Cidofovir in children
with RLP, complying with a protocol adopted in our services
since 2002.
MATERIAL AND METHOD
In this trial we have included 5 children who have
been followed up for at least one year as outpatients, follow-
up in our pediatric laryngology clinic and who have complied
with a protocol for Cidofovir use. They all have agreed to
sign a Free Informed Consent Form, as determined by the
standards of the Ethics and Research Committee, Medical
School, Federal University of Sao Paulo.
In order to be included in this protocol, the patients
had to comply with some inclusion and exclusion criteria:
A. Inclusion Criteria:
1. Diagnosis confirmed by clinical pathology analysis.
2. At least two relapses after surgical procedure.
3. Material collection for HPV typing.
B. Exclusion Criteria:
1. Chronic use of hepatotoxicity drugs.
2. Liver disorders.
3. Kidney disorders.
After inclusion and exclusion criteria were met, the
protocol consisted of surgical treatment with suspension
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laryngoscopy with cold steel removal of papillomatosis
lesions and local injection of Cidofovir (concentration and
dose of 7.5mg/ml) up to 3 ml. These children were submitted
to a cycle at least for 3 applications within intervals of 2-3
weeks, when no lesions occurred. In case there were signs
of lesion relapse, the lesion was removed and a new cycle
of applications began.
When tracheal site was affected, the same dose was
used after the removal of the lesions, via bronchoscopy with
the use of a 0º and 4 mm non-flexible endoscope and with
cup forceps.
All the lesions removed in the procedure were sent
to clinical pathology analysis. Part of the lesion was removed
before starting the use of Cidofovir and sent to a Molecular
Biology laboratory to check HPV typing. The proposed
typing test was done by PCR (Polymerase Chain Reaction).
After each application, we requested new laboratorial
exams such as blood count, alkaline phosphatase, gamma-
GT, TGO, TGP, urea and creatinine.
These children were followed up every 2 weeks with
video nasofibroscopy and video laryngoscopy (whenever
possible). At any sign of relapse, they were submitted to
debulking and a new cycle of 3 applications began, as
recommended. After a 2-month relapse-free period, they
were submitted to monthly follow-up consisting of video
nasofibroscopy and video laryngoscopy for early detection
of any sign of relapse.
We have adopted the protocol described above to
observe the patients response to the adopted therapy in a
standardized way.
OUTCOMES
In this preliminary trial, we have included 5 children
who had been followed up for more than one year: 3 were
males and 2 females, ages ranging from 3 to 9 years of age,
mean age: 5.2 years. Among these children, only one had
tracheotomy and had the disease spread to the lower airways.
Child number 1, male, 6 years, born and coming
from Aracaju, who had already undergone 5 previous
surgeries in intervals of approximately 2 months between
each procedure. He was included in the protocol and
submitted to total of 9 applications of Cidofovir. After 6
applications, he had no relapses for a 11-month period, after
which he showed a small lesion focus in the left vocal fold
(asymptomatic); he was, then, submitted to a new 3-
application cycle and has now been followed up for 1 year
and 2 months with no signs of relapse. His typing for HPV
detected HPV-11.
Child number 2, male, 5 years, born and coming
from Rio de Janeiro, had already been submitted to 10
previous surgeries and had been, by that time,
tracheotomized for one year. The disease had spread through
the whole trachea to the carina. The interval between
procedures was approximately of 2-3 months. After his
inclusion in our protocol, he was submitted to 9 applications
of Cidofovir in the larynx and in the trachea. After the 5th
Cidofovir application, he was decannulated. Currently, he
has been followed up for 1 year and 3 months. It was not
possible to have his HPV typing but the material is stored in
the Molecular Biology laboratory, in perfect conditions to
preserve the virus structure.
Child number 3, male, 3 years, born and living in
Sao Paulo, had already undergone 4 previous surgeries with
1-2 months intervals between procedures. After his inclusion
in the protocol, he was submitted to 10 Cidofovir applications.
Currently, in a follow-up of 1 year and 3 months, he shows
no signs of relapse. The HPV type responsible for RLP in
this patient was type HPV-6.
Child number 4, female, 3 years, born and coming
from Maranhão, had already been submitted to 3 surgeries
in intervals of 3 months, approximately. After her inclusion
in the protocol, she received 5 applications of Cidofovir.
Recurrences were controlled for 11 months when a small
lesion focus appeared in the vestibular fold. As Cidofovir
was not available at the moment, we decided to wait and
see. She has been followed up every month for the past 5
months and the lesion focus showed discreet growth in size
but it is still asymptomatic. The child has had no symptoms
for 1 year and 4 months. The material for performing the
typing test is also stored at the Molecular Biology laboratory.
Child number 5, female, 9 years, born and living in
Sao Paulo, had already undergone 3 previous surgeries in
intervals of 3 months between procedures. After her inclusion
in the protocol, she received 5 applications of Cidofovir and
remained free of recurrences for 12 months. Later, she showed
a small lesion in the vestibular face of the right vocal fold.
Then, we started a new 3-application cycle. However, as
the patient did not show up for the third application, she
only received two. At the same time, as she did not regularly
comply with follow-up schedules, she has been excluded
from the protocol. She remained in the follow-up program
as an outpatient and has had no recurrence for a whole year.
Currently, she showed a small lesion in the right vocal fold,
which is still asymptomatic. The material collected for HPV
typing is also stored in the Molecular Biology laboratory.
In all five children, we had good control of recurrent
lesions when we compared the intervals between surgeries
before and after the use of the medication.
No child showed any type of change in the laboratorial
exams and no local or systemic side effect with the local
injection of Cidofovir.
DISCUSSION
Several authors have demonstrated positive results
with the use of Cidofovir in RLP patients. Pransky et al. in
1999 and 200020,21 were the first researchers to demonstrate
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results in pediatric patients. In their first study, they had a
series of 5 children and used Cidofovir in an initial
concentration of 2.5mg/ml with maximum dosage of 1mg/
kg. During the study, they increased the concentration to
5mg/ml, in applications of 1 to 2 ml, and the total dosage
they used ranged from 2.5 to 10 mg, in intervals of 2-3
weeks. In their second study, they added 5 more children in
their series and maintained the same concentration (5mg/
ml), but they administered 2 to 4 ml per application and
performed at least 4 applications in intervals of 2 weeks.
They also recommended previous debulking. Snoeck16 and
Willian22, on the other hand, presented different
methodologies: they performed local application of Cidofovir
without any debulking (lesion removal). Snoeck, who was a
pioneer in the use of Cidofovir for RLP, recommended a
concentration of 2.5mg/ml and applied the medication until
the lesions disappeared, but he only studied the adult
population.
Although there are some studies with the use of
Cidofovir, the methodology published in the literature vari-
es a lot and there is no consensus regarding the ideal dose
to be used, the number of applications and the interval
between applications. Besides, some authors favor local
application only on the lesions, whereas other authors
associate the lesions exeresis with local application of the
medication.
In our series, we have been using Cidofovir for almost
4 years and have had excellent results in adults25. In these
patients the procedure was to perform surgical removal of
the lesions and administer 18mg of Cidofovir, and new
applications only when lesion relapses occurred.
When we started using the medication in children,
we observed that the results were not as positive as the
results previously observed in adults. Then, we started to
use a protocol based on the one used by Pransky, in which
we applied Cidofovir at least 4 times in intervals of 2 weeks.
But the concentration and the doses we used (7.5mg/ml up
to 3 ml) were higher than those recommended in the
literature. We agreed with Pransky methodology regarding
the association of lesions removal with Cidofovir application,
especially in the pediatric population where the diameter
of the upper airways is smaller, thus, with higher risk of
obstruction.
In our outcomes with these 5 children we have
observed good recurrence control when we compared the
intervals between surgeries before starting the treatment
and after the use of the medication. Before the applications
of Cidofovir, these 5 children had recurrences in shorter
intervals (1 to 3 months), which required surgical
procedures. After their inclusion in the protocol, there was
a change in the disease evolution in the 5 children, as they
remained free of recurrences during at least one year.
Moreover, the recurrences in patients numbers 4 and 5
could only be noticed due to our strict follow-up because
these patients remained asymptomatic. Milczuk, in 200323,
also had positive outcomes in 4 children who were treated
with Cidofovir.
Nevertheless, we observed that we had to have
several applications to obtain good response and patients 1,
2 and 3 – who have received 9 to 10 Cidofovir applications,
achieved better outcomes and were free of disease for more
than 14 months.
We believe that these children – maybe because
they have a more aggressive type of recurrent laryngeal
papillomatosis – need heavier doses and higher number of
Cidofovir applications than adults do. The dosage used in
our protocol is a little higher than the doses described in
literature up to now20,21,23,24. These patients needed more
than one 3-application cycle to achieve good control of
recurrences. However, these children did not have any type
of changes in their laboratorial exams, clinical pathology
analysis and also did not show any local or systemic side
effect, as in accordance to other cases in the literature
15,16,20,21,26. The only study described in the literature that
reports side effects with local use of Cidofovir was published
by Bienvenu27 in 2002. This was the report of a case study
with an immunodepressed patient, with previous chronic
renal failure who developed an extensive acuminate
condyloma and who was, then, submitted to local
application of Cidofovir in gel 4% for 12 continuous days.
Although there was lesion involution, on the 19th day the
patient developed acute renal failure. The author
underlined that the patient had received a higher dose
than those described by other authors and had genital
excoriations during treatment and, in addition, suffered from
chronic renal failure. Considering all previous conditions
affecting this patient, we do not believe that this case should
be relevant when analyzing the side effects in the local
use of Cidofovir.
Although HPV typing by Molecular Biology (PCR) is
part of the protocol, due to budget limitations, we were
only able to obtain the typing for patients 1 and 3. The
material from the other patients has been collected and is
stored for further typing as soon as possible.
Based on the preliminary outcomes, we consider
Cidofovir as a promising therapy to control recurrent
laryngeal papillomatosis in children with aggressive form
of the disease. The protocol in use allowed us to
standardize the dose, to choose the proper moment to
perform new applications, and also to have close
observation to check possible recurrences. Nevertheless,
our follow-up is not long enough to report any cure. This
is a new therapy (little bit more than 5 years); thus, we
must have strict follow-up of these patients and develop
study protocols with larger number of patients and longer
follow-up periods. Bearing in mind this purpose, we con-
tinue to develop this protocol in our service and to include
new patients.
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